FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Breast Cancer

Efficacy was evaluated in the DESTINY-Breast01 trial
23 Dec 2019
Anticancer agents & Biologic therapy;  Breast cancer

On 20 December 2019, the US Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU®, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Efficacy was investigated in DESTINY-Breast01 (NCT03248492), a multicentre, single-arm trial enrolling 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies. Patients received fam-trastuzumab deruxtecan-nxki 5.4 mg/kg by intravenous infusion every 3 weeks until unacceptable toxicity or disease progression.

The main efficacy outcome measures were confirmed objective response rate (ORR) assessed by independent central review using RECIST v1.1 and response duration. The ORR was 60.3% (95% CI: 52.9, 67.4), with a 4.3% complete response rate and a 56% partial response rate. Median response duration was 14.8 months (95% CI: 13.8, 16.9).

The safety was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of fam-trastuzumab deruxtecan-nxki 5.4 mg/kg in DESTINY-Breast01 and Study DS8201-A-J101 (NCT02564900).

The most common adverse reactions (frequency ≥20%) to fam-trastuzumab deruxtecan-nxki were nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anaemia, neutropenia, diarrhoea, leukopenia, cough, and thrombocytopenia. The prescribing information includes a Boxed Warning to advise health professionals of the risk of interstitial lung disease (ILD) and embryo-foetal toxicity. Fatal outcomes due to ILD occurred in 2.6% of patients.

The recommended fam-trastuzumab deruxtecan-nxki dose is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

Full prescribing information for ENHERTU is available here

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate FDA’s assessment. FDA granted this application Breakthrough Therapy designation. Fam-trastuzumab deruxtecan-nxki also was granted fast-track designation and priority review. This application was approved 4 months ahead of the FDA goal date.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings